E.g., 04/23/2018
E.g., 04/23/2018

2007 Financial Results

17 March, 2008

2007: Clear improvement in growth and in operating margin before non-recurring items

FDA Clears bioMérieux's VIDAS® NT-proBNP, a High Medical Value Test for Diagnosis of Heart Failure

13 March, 2008

bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure.

bioMérieux's Food Safety Handbook is Now Available

26 February, 2008

bioMérieux, a world leader in industrial microbiology control, announces that the first Food Safety Handbook: Microbiological Challenges is now available for food professionals. Published by bioMérieux Editions, the handbook was developed with contributions from 24 internationally renowned experts.

bioMérieux and Wescor Bring a New Gram Staining Instrument for Enhanced Microbiology Laboratory Workflow

14 February, 2008

bioMérieux (Euronext: BIM) and Wescor, an ELITech Group Company have signed an agreement by which bioMérieux will become Wescor’s exclusive worldwide partner for marketing two customized slide stainer instruments for Gram and tuberculosis bacillus under the bioMérieux brand.

bioMérieux and Shanghai Kehua Bio-Engineering Build Joint Venture

31 January, 2008

Shanghai Kehua Bio-engineering (Stock Code: 002022) and bioMérieux (Euronext: BIM) announce the creation of a Shanghai-based joint venture to which bioMérieux will transfer microplate immunoassay manufacturing currently located at its Boxtel site in the Netherlands.

2007 Business Review

22 January, 2008

Sales up 7.4% like-for-like

Quidel and bioMérieux Announce a Global Strategic Alliance in Rapid Diagnostics

15 January, 2008

Quidel Corporation (NASDAQ: QDEL) and bioMérieux (Euronext: BIM) have agreed to form a long-term global alliance in the area of rapid clinical diagnostics for the point-of-care. bioMérieux will become Quidel’s primary distributor for its QuickVue® rapid diagnostic tests outside the United States and the two companies intend to co-develop new rapid tests using Quidel’s market leading rapid test development capability and bioMérieux’s expertise and extensive library of antibodies and antigens. The companies will especially leverage their mutual expertise in the area of infectious diseases.

Sysmex and bioMérieux Form a Commercial Joint Venture for the Japanese in Vitro Diagnostics Market

10 January, 2008

Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) and bioMérieux (Euronext: BIM) announce they have signed an agreement by which Sysmex will take a 34% equity stake in bioMérieux Japan, Ltd.

bioMérieux Transfers Certain R&D and Manufacturing Activities to France

08 January, 2008

bioMérieux (Euronext: BIM) announces the transfer to France of R&D and certain manufacturing activities currently at its Boxtel site in the Netherlands. The transfer will take place gradually until the end of 2009, when this site closes.

Pioneering Diagnostics